Larry Glass - Neuren Pharmaceuticals Insider

NURPF -- USA Stock  

USD 0.92  0.00  0.00%

  CEO
Mr. Larry Glass was Chief Science Officer and Executive Director of Neuren Pharmaceuticals Limited since September 2, 2013. He is a seasoned manager with more than 30 years in the life sciences industry. Before he joined Neuren, he worked as an independent consultant for a number of biotech companies in the US and internationally, providing management, strategic and business development services. Prior to that, he was CEO of a contract research organisation that provided preclinical research and clinical trials support for major pharmaceutical and biotechnology companies and the US government. For a number of years, the CRO operated as a subsidiary of a NYSElisted company and was subsequently sold to a European biopharmaceutical enterprise which was then acquired by Johnson Johnson.
  CEO Since 2013      
61 3 9092 0480  http://www.neurenpharma.com

Management Efficiency

The company has return on total asset (ROA) of (39.89) % which means that it has lost $39.89 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of 29.66 % meaning that it generated $29.66 on every $100 dollars invested by stockholders.

Similar Executives

Showing few of many executives

CEO Since

Jan WinkelGenmab AS
2010
Javier RibesGrifols S A
2015
Albert RouraGrifols S A
2014
Peder NielsenNovozymes AS
2013
Victor DeuGrifols S A
2017
Geoffrey McDonoughSwedish Orphan Biovitrum AB
2011
Albert RouraGrifols S A
2014
Onno StolpeGalapagos NV
1999
Howard RobinNektar Therapeutics
2007
Victor DeuGrifols S A
2017
Flemming OrnskovShire plc
2013
Jose FullaGrifols S A
2017
Jose FullaGrifols S A
2017
Guido OelkersSwedish Orphan Biovitrum AB
2017
Ping TseSino Biopharmaceutical Limited
2016
Javier RibesGrifols S A
2015

Entity Summary

Neuren Pharmaceuticals Limited, a biopharmaceutical company, engages in the development of therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Neuren Pharmaceuticals Limited was incorporated in 1993 and is based in Auckland, New Zealand. Neuren Pharmaceuticals is traded on OTC Market in USA.Neuren Pharmaceuticals Limited (NURPF) is traded on OTC Market in USA. It is located in PWC Tower and employs 10 people.

Neuren Pharmaceuticals Leadership Team

Joseph Horrigan, VP of Clinical Devel. and Medical Affairs
Larry Glass, CEO, Managing Director
Bruce Hancox, Independent Non-Executive Director
Jenny Harry, Non-Executive Independent Director
James Shaw, COO
Patrick Davies, Non-Executive Independent Director
Dianne Angus, Non-Executive Independent Director
Richard Treagus, Executive Chairman of the Board
Trevor Scott, Independent Non-Executive Director
Jon Pilcher, CFO, Company Secretary

Stock Performance Indicators

Did you try this?

Run Equity Search Now

   

Equity Search

Search for activelly-traded equities including funds and ETFs from over 30 global markets
All  Next Launch Equity Search

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see also Stocks Correlation. Please also try Cryptocurrency Arbitrage module to find pairs of digital assets on multiple exchanges that are traded at a risk free arbitrage.
Search macroaxis.com